Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-β receptor

Leukemia Research

Volumn 23, Issue 12, 1999, Pages 1105-1112

  Jung, Chul W ^a   Kim, Eun S ^b   Seol, Jae G ^b   Park, Woo H ^b   Lee, Sang J ^a   Kim, Byoung K ^b   Lee, Young Y ^b,c  

^a Chung Ang University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

EB1089; HL 60; p27; Transforming growth factor receptor; Transforming growth factor 1; Vitamin D receptor

Indexed keywords

COLECALCIFEROL; CYCLIN DEPENDENT KINASE; NEUTRALIZING ANTIBODY; SEOCALCITOL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; CALCITRIOL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GROWTH INHIBITORS; HL-60 CELLS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CALCITRIOL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 0032727760     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00136-8     Document Type: Article

References (49)

1. Koeffler H.P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 62:1983;708.
2. Munker R., Norman A.W., Koeffler H.P. Vitamin D compounds: effect on clonal proliferation and differentiation of human myeloid cells. J. Clin. Invest. 78:1986;424.
3. 3 analogues: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep. 69:1985;1399.
4. Mehta A.B., Kumaran T.O., Marsh G.W. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet. 2:1984;761.
5. 3. Am. J. Hematol. 23:1986;284.
6. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 44:1992;2273.
7. James S.Y., Mackay A.G., Binderup L., Colston K.W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol. 141:1994;555.
8. 3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. Leukemia. 10:1996;1751.
9. WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest. 95:1995;973.
10. 3-treated HL60 cells. Cancer Res. 57:1997;2851.
11. Massagué J. The transforming growth factor-beta family. Ann. Rev. Cell. Biol. 6:1990;597.
12. Moses H.L., Coffey Jr R.J., Leof E.B., Lyons R.M., Keski-Oja J. Transforming growth factor β regulation of cell proliferation. J. Cell. Physiol. 5:1987;1.
13. Alexandrow M.G., Moses H.L. Transforming growth factor β and cell cycle regulation. Cancer Res. 55:1995;1452.
14. Hino M., Tojo A., Miyazono K., Urabe A., Takaku F. Effects of type β transforming growth factors on hematopoietic progenitor cells. Br. J. Haematol. 70:1988;143.
15. Ottmann O.G., Pelus L.M. Differential proliferation effects of transforming growth factor-β on human hematopoietic progenitor cells. J. Immunol. 140:1988;2661.
16. Ewen M.E., Sluss H.K., Whitehouse L.L., Livingston D.M. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell. 74:1993;1009.
17. Geng Y., Weinberg R.A. Transforming growth factor-β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. 90:1993;10315.
18. Satterwhite D.J., Aakre M.E., Gorska A.E., Moses H.L. Inhibition of cell growth by TGFβ is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells. Cell Growth Differ. 5:1994;789.
19. Falk L.A., De Benedetti F., Lohrey N., Birchenall-Roberts M.C., Ellingsworth L.W., Faltynek C.R. et al. Induction of transforming growth factor-β1 (TGF-β1) receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: possible TGF-β1-mediated autocrine inhibition. Blood. 77:1991;1248.
20. Taipole J., Matikainen S., Hurme M., Keski-Oja J. Induction of transforming growth factor-β1 and its receptor expression during myeloid leukemia cell differentiation. Cell Growth Differ. 5:1994;1309.
21. Nunes I., Kojima S., Rifkin D.B. Effects of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid-treated HL-60 cells. Cancer Res. 56:1996;495.
22. Turley J.M., Falk L.A., Ruscetti F.W., Kasper J.J., Francomano T., Fu T. et al. Transforming growth factor β functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Differ. 7:1996;1535.
23. 3 enhances antiproliferative effect and transcription of TGF-β on human keratinocytes in culture. J. Cell. Physiol. 151:1992;579.
24. 3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 55:1995;1540.
25. 3 on leukemic cells. In Vitro Cell Dev. Biol. 26:1990;682.
26. 3-induced monocytic differentiation of myeloid leukemia cells. Anticancer Res. 11:1991;181.
27. 3-induced terminal monocytic differentiation of human leukemic cell lines. J. Immunol. 150:1993;2418.
28. 3 and retinoid. J. Cell. Physiol. 178:1999;109.
29. 3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leukemia Res. 18:1994;453.
30. 3 response element. Leukemia Res. 19:1995;147.
31. Taetle R., Payne C., Dos Santos B., Russel M., Segarini P. Effect of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res. 53:1993;3386.
32. Murohashi I., Endho K., Nishida S., Yoshida S., Jinnai I., Bessho M. et al. Differential effects of TGF-β1 on normal and leukemic human hematopoietic cell proliferation. Exp. Hematol. 23:1995;970.
33. Drexler H.G., Meyer C., Zaborski M., Uphoff C.C., Quentmeier H. Growth-inhibitory effects of transforming growth factor-β1 on myeloid leukemia cell lines. Leukemia. 22:1998;927.
34. Sing K.G., Keller J.R., Ellingsworth L.R., Ruscetti F.W. Transforming growth factor-β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood. 72:1988;1504.
35. De Benedetti F., Falk L.A., Ellingsworth L.R., Ruscetti F.W., Faltynek C.R. Synergy between transforming growth factor-β and tumor necrosis factor-α in the induction of monocytic differentiation of human leukemic cell lines. Blood. 75:1990;626.
36. 3 increases transforming growth factor β and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem. Biophys. Res. Commun. 239:1997;734.
37. 3 in MG-63 osteoblastic cells: possible involvement of regulation of TGF-β type II receptor. Biochem. Biophys. Res. Commun. 204:1994;918.
38. 3 synergism toward transforming growth factor β1-induced AP-1 transcriptional activity in mouse osteoblastic cells via it's nuclear receptor. J. Biol. Chem. 273:1998;14738.
39. Sing G., Ruscetti F., Beckwith M., Keller J., Ellingsworth L., Urba W. et al. Growth inhibition of a human lymphoma cell line: Induction of a transforming growth factor β1 autocrine negative loop by phorbol myristate acetate. Cell Growth Differ. 1:1990;549.
40. Lucas C., Bald L.N., Fendly B.M., Mora-Worms M., Figari I.S., Patzer E.J. et al. The autocrine production of transforming growth factor β1 during lymphocyte activation: a study with a monoclonal antibody-based ELISA. J. Immunol. 145:1990;1415.
41. 3 receptor mRNA in human leukemia cells HL-60. Cell Prolif. 24:1991;159.
42. Inaba M., Okuno S., Koyama H., Nishizawa Y., Morii H. Dibutyryl cAMP enhances the effect of 1,25-dihydroxyvitamin D3 on a human promyelocytic leukemia cell, HL-60, at both receptor and the postreceptor steps. Arch. Biochem. Biophys. 293:1992;181.
43. 3. Exp. Hematol. 26:1998;198.
44. 3 receptor in HL-60 cells and related subclones. Mol. Cell. Endocrinol. 95:1993;51.
45. 3 in HL60 cells. Cancer Res. 56:1996;264.
46. 3 reverses the G1 block but not differentiation of HL60 cells. Leukemia. 12:1998;1256.
47. Asou H., Koike M., Elstner E., Cambell M., Le J., Uskokovic M.R. et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood. 92:1998;2441.
48. Polyak K., Lee M.H., Erdjument-Bromaga H., Koff A., Roberts J.M., Tempst P. et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitotic signals. Cell. 78:1994;59.
49. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67.